Amgen’s olpasiran reduces cardiovascular disease risk factor in Phase II study

Olpasiran reduced lipoprotein(a) levels by more than 95% in patients with established atherosclerotic cardiovascular disease. Credit: Robina Weermeijer on Unsplash.